FNCH News and Press, Finch Therapeutics Group Inc. From 05/10/23

SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today repo...

2023-04-25 17:08:37 ET Finch Therapeutics ( NASDAQ: FNCH ) on Tuesday said it had appointed Matthew Blischak as CEO, effective May 16. The company said current CEO Mark Smith will conclude his role as top boss effective May 15. FNCH also announced the appointment o...

2023-04-19 10:32:41 ET If you’re looking for penny stocks to buy now, there’s a lot to account for in the stock market today. Whether it’s the overarching recession and inflation story or the underpinnings of a potential stock market crash in 2023, emotions are ridi...

SOMERVILLE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today an...

2023-04-03 08:43:08 ET Summary Finch Therapeutics recently made the decision to discontinue the company's Phase 3 trial, lay off 95% of its workforce, and pursue the next path to maximize value for shareholders. As of now, the company has a market cap of $16 million with a cash po...

2023-03-23 16:43:21 ET Finch Therapeutics press release ( NASDAQ: FNCH ): Q4 GAAP EPS of -$0.56. Cash and cash equivalents as of December 31, 2022 was $71.0 million, compared to $133.5 million as of December 31, 2021. Finch expects that the cash and cash equivalents it had...

SOMERVILLE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today re...

Summary April 26 is FDA decision day for SER-109, the Seres microbiome treatment for recurrent C. difficile infection. Finch Therapeutics gives up on Phase 3 trial for C. difficile recurrence; lays off 95% of staff. FNCH is a casualty of setbacks at the beginning of the new medical ...

Finch Therapeutics ( NASDAQ: FNCH ) is discontinuing a phase 3 trial of its bacterial infection drug CP101 and reducing its workforce by ~95%. The company noted that it will discontinue the late-stage study, dubbed PRISM4, of microbiome candidate CP101 in recurrent...

SOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (the “Company,” “Finch,” or “Finch Therapeutics”) (Nasdaq: FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile ...